Profound Medical to Showcase TULSA Procedure at AUA Meeting, Explores PSMA PET Integration
PROF sits 91% above its 52-week low of $3.76 on light trading volume (0.2× avg).
Summary
Profound Medical announced that its TULSA Procedure will be featured in four oral presentations at the upcoming American Urological Association's Annual Meeting and is launching an initiative to integrate PSMA PET imaging for enhanced treatment planning.
Key Events · Product Development and Regulatory · PROF
-
TULSA Procedure Featured at AUA2026
The company's TULSA Procedure will be highlighted in four oral presentations at the American Urological Association's Annual Meeting on May 16, 2026, increasing visibility and scientific validation.
-
New PSMA PET Imaging Integration Initiative
Profound Medical is exploring the integration of PSMA PET molecular imaging technologies with the TULSA Procedure to enhance ablation planning and patient monitoring, indicating ongoing product development.
Analysis · PROF · Industrial Applications And Services
This filing highlights Profound Medical's continued advancements and market presence for its TULSA Procedure. Four oral presentations at the American Urological Association's Annual Meeting provide significant visibility and validation for the technology. Additionally, the initiative to integrate PSMA PET molecular imaging suggests ongoing product innovation aimed at enhancing treatment planning and patient monitoring, which could expand the procedure's utility and adoption. This builds on recent positive news, including strong financial results and successful clinical trial outcomes.
At the time of this filing, PROF was trading at $7.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $261.6M. The 52-week trading range was $3.76 to $8.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.